Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
12.04
+0.39 (3.35%)
Aug 25, 2026, 4:00 PM EDT - Market closed

Zevra Therapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Zevra Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $25. The average 1-year stock price forecast is 107.64% higher than the current stock price, while the lowest is $20 (+66.11%) and the highest is $35 (+190.70%).

Price Target: $25 (+107.64%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$20$25$24$35
Change+66.11%+107.64%+99.34%+190.70%

Analyst Ratings

The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy777777
Buy222222
Hold000000
Sell000000
Strong Sell000000
Total999999

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$26
BuyReiterates$26+115.95%Aug 20, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$20
BuyReiterates$20+66.11%Aug 12, 2026
Maxim Group
Maxim Group
Buy
Maintains
$35
BuyMaintains$35+190.70%Aug 7, 2026
Guggenheim
Guggenheim
Buy
Maintains
$24$23
BuyMaintains$24$23+91.03%Aug 7, 2026
Roth MKM
Roth MKM
Buy
Maintains
$21
BuyMaintains$21+74.42%Aug 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
152.22M
from 106.47M
Increased by 42.97%
Revenue Next Year
176.98M
from 152.22M
Increased by 16.27%
EPS This Year
1.14
from 1.35
Decreased by -15.56%
EPS Next Year
1.05
from 1.14
Decreased by -7.89%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
28.65M10.16M27.46M23.61M106.47M152.22M
Revenue Growth
115.61%-64.53%170.26%-14.02%350.92%42.97%
Gross Profit
26.59M9.94M25.29M16.20M89.99M144.27M
Gross Margin
92.81%97.82%92.09%68.59%84.52%94.78%
Operating Income
7.73M-24.90M-49.60M-87.00M-4.23M79.66M
Net Income
-8.56M-26.77M-46.05M-105.51M83.23M68.31M
EPS
----1.351.14
EPS Growth
------15.56%
Forward PE
24.17102.50102.50102.5019.1510.56
Free Cash Flow
6.31M-10.00M-10.32M-36.36M-1.96M49.88M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High158.6M
Avg152.2M
Low148.3M

Revenue Growth

Revenue Growth202620272028
High
49.0%
Avg
43.0%
Low
39.3%

EPS Forecast

EPS202620272028
High1.27
Avg1.14
Low1.04

EPS Growth

EPS Growth202620272028
High
-5.9%
Avg
-15.6%
Low
-23.0%